Journal
CURRENT ONCOLOGY REPORTS
Volume 22, Issue 3, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-020-0885-0
Keywords
AML; Niche; Microenvironment; Bone marrow; Stromal cells; CXCR4; CXCL12; Acute myeloid leukaemia; DNMT3A; Leukaemic stem cell; Blast; Mesenchymal cells; T cells; Stroma
Categories
Funding
- National institute for Health Research (NIHR) Academic Clinical Fellowship award
- Bloodwise, UK
Ask authors/readers for more resources
Purpose of Review Acute myeloid leukaemia (AML) is a heterogeneous malignancy for which treatment options remain suboptimal. It is clear that a greater understanding of the biology of the AML niche will enable new therapeutic strategies to be developed in order to improve treatment outcomes for patients. Recent Findings Recent evidence has highlighted the importance of the bone marrow microenvironment in protecting leukaemia cells, and in particular leukaemic stem cells from chemotherapy-induced cell death. This includes mesenchymal stem cells supporting growth and preventing apoptosis, and altered action and secretion profiles of other niche components including adipocytes, endothelial cells and T cells. Here, we provide a detailed overview of the current understanding of the AML bone marrow microenvironment. Clinical trials of agents that mobilise leukaemic stem cells from the bone marrow are currently ongoing and show early promise. Future challenges will involve combining these novel therapies targeted at the AML niche with conventional chemotherapy treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available